» Articles » PMID: 20687162

Sample Size Determination in Clinical Trials with Multiple Co-primary Binary Endpoints

Overview
Journal Stat Med
Publisher Wiley
Specialty Public Health
Date 2010 Aug 6
PMID 20687162
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Clinical trials often employ two or more primary efficacy endpoints. One of the major problems in such trials is how to determine a sample size suitable for multiple co-primary correlated endpoints. We provide fundamental formulae for the calculation of power and sample size in order to achieve statistical significance for all the multiple primary endpoints given as binary variables. On the basis of three association measures among primary endpoints, we discuss five methods of power and sample size calculation: the asymptotic normal method with and without continuity correction, the arcsine method with and without continuity correction, and Fisher's exact method. For all five methods, the achieved sample size decreases as the value of association measure increases when the effect sizes among endpoints are approximately equal. In particular, a high positive association has a greater effect on the decrease in the sample size. On the other hand, such a relationship is not very strong when the effect sizes are different.

Citing Articles

Bayesian Multivariate Logistic Regression for Superiority and Inferiority Decision-Making under Observable Treatment Heterogeneity.

Kavelaars X, Mulder J, Kaptein M Multivariate Behav Res. 2024; 59(4):859-882.

PMID: 38733304 PMC: 11548885. DOI: 10.1080/00273171.2024.2337340.


Bayesian multilevel multivariate logistic regression for superiority decision-making under observable treatment heterogeneity.

Kavelaars X, Mulder J, Kaptein M BMC Med Res Methodol. 2023; 23(1):220.

PMID: 37798704 PMC: 10552398. DOI: 10.1186/s12874-023-02034-z.


Innovative thinking of clinical investigation for rare disease drug development.

Wang P, Chow S Orphanet J Rare Dis. 2023; 18(1):299.

PMID: 37740206 PMC: 10517458. DOI: 10.1186/s13023-023-02909-w.


Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints.

Meyer E, Mesenbrink P, Di Prospero N, Pericas J, Glimm E, Ratziu V PLoS One. 2023; 18(3):e0281674.

PMID: 36893087 PMC: 9997886. DOI: 10.1371/journal.pone.0281674.


Power analyses for stepped wedge designs with multivariate continuous outcomes.

Davis-Plourde K, Taljaard M, Li F Stat Med. 2022; 42(4):559-578.

PMID: 36565050 PMC: 9985483. DOI: 10.1002/sim.9632.